Advertisement

Klinisch-elektrophysiologische Effekte von Amiodaron bei bedrohlichen ventrikulären Tachyarrhythmien

  • M. Borggrefe
  • A. Podczeck
  • G. Breithardt
Conference paper

Zusammenfassung

Amiodaron, ein Benzofuranderivat, wurde 1961 bei Labaz entwickelt (1, 2) und ursprünglich als antianginöse wirksame Substanz in die Klinik eingeführt (3, 4). Erst später wurden die potenten antiarrhythmischen Eigenschaften der Substanz bekannt, die der Klasse III nach Vaughan-Williams zuzuordnen sind (5–7). Inzwischen liegen zahlreiche Studien vor, die die Wirksamkeit von Amiodaron bei einer Vielzahl therapierefraktärer supraventrikulärer und ventrikulärer Tachyarrhythmien belegen (8–32). Die pharmakologischen Eigenschaften von Amiodaron mit einer langen Halbwertzeit erleichtern zwar die chronische Einnahme, bedingen andererseits aber auch Probleme bei der Wahl seiner optimalen Aufsättigungs- und Erhaltungsdosis. Diese komplexen Zusammenhänge und die potentiell ernsten Nebenwirkungen (16, 33–34) lassen Amiodaron zu einer Sustanz werden, die nur bei bedrohlichen Tachyarrhythmien, die sich gegenüber anderen, konventionellen Antiarrhythmika als ineffektiv erwiesen haben, eingesetzt werden sollte.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Charlier R, Deltour G, Tondeur R, Binon F (1962) Recherches dans la serie des benzofurannes. VII. Etude pharmacoligique préliminaire due butyl-2 (diiode-3′, 5′-beta-N-diethylamino-ethoxy-4′ benzoyl)-3 bezonfu- ranne. Arch Intern Pharmacodyn Ther 139: 255–264Google Scholar
  2. 2.
    Charlier R, Delaunois G, Bautheri J et al (1969) Dans la serie des benzofurannes. XL. Properties antiarrhythmiques de amiodarone. Cardiologia 54: 82CrossRefGoogle Scholar
  3. 3.
    Charlier R, Deltaur G, Baudine A (1968) Pharmacology of amiodarone, an antianginal drug with new biologic profile. Arzneimittelforsch 18: 1408PubMedGoogle Scholar
  4. 4.
    Vastesaeger M, Gillot P, Rassons G (1967) Etude clinique d’une nouvelle médication antiangoreuse. Acta Cardiol (Belgium) 22: 483: 500Google Scholar
  5. 5.
    Singh B, Vaughan Williams E (1970) The effect of amiodarone, a new antianginal drug on cardiac muscle. Br J Pharmacol 39: 657PubMedGoogle Scholar
  6. 6.
    Rosenbaum M, Chiale P, Halpern M (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38: 934PubMedCrossRefGoogle Scholar
  7. 7.
    Sing BN, Collet J, Chow C (1980) New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 22: 243CrossRefGoogle Scholar
  8. 8.
    Nademanee K, Hendrickson, J, Cannom DS et al (1981) Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 6: 759CrossRefGoogle Scholar
  9. 9.
    Heger JJ, Prystowsky EN, Jackman WM et al (1981) Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305: 539PubMedCrossRefGoogle Scholar
  10. 10.
    Hamer AW, Finerman WB, Peter T et al (1981) Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 102: 992PubMedCrossRefGoogle Scholar
  11. 11.
    Waxman HL, Groh WC, Marchlinski FE et al (1982) Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients. Am J Cardiol 50: 1066PubMedCrossRefGoogle Scholar
  12. 12.
    Saksena S, Rothbart ST, Cappello G (1983) Chronic effects of amiodarone in patients with refractory ventricular tachycardia. Int J Cardiol 3: 339PubMedCrossRefGoogle Scholar
  13. 13.
    Nademanee K, Singh BN, Hendrickson J et al (1983) Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 98: 577PubMedGoogle Scholar
  14. 14.
    Haffajee CI, Love JC, Canada AT et al (1983) Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 67: 1347PubMedCrossRefGoogle Scholar
  15. 15.
    Morady F, Sauve MJ, Maline P et al (1983) Long-term efficacy and toxicity of high dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 52: 975PubMedCrossRefGoogle Scholar
  16. 16.
    Greene HL, Graham EL, Werner JA et al (1983) Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 2: 1114PubMedCrossRefGoogle Scholar
  17. 17.
    McGovern B, Garan H, Malacoff RF et al (1984) Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53: 1558PubMedCrossRefGoogle Scholar
  18. 18.
    Marchlinski FE, Buxton AE, Flores BT et al (1985) Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. Am J Cardiol 55: 709PubMedCrossRefGoogle Scholar
  19. 19.
    Horowitz LN, Greenspan AM, Spielman SR et al (1985) Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55: 367PubMedCrossRefGoogle Scholar
  20. 20.
    Reddy CP, Kuo CS, Jivraijka V (1984) Effect of amiodarone on electric induction, morphology, and rate of ventricular tachycardia and its relation to clinical efficacy. PACE 7: 1055PubMedGoogle Scholar
  21. 21.
    Veltri EP, Reid PR, Platia EV et al (1985) Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. Am J Cardiol 55: 375PubMedCrossRefGoogle Scholar
  22. 22.
    Veltri EP, Reid PR, Platia EV et al (1985) Amiodarone in the treatment of life-threatening ventricular tachycardia: Role of Holter monitoring in predicting long-term clinical efficacy. J Am Coll Cardiol 6: 806PubMedCrossRefGoogle Scholar
  23. 23.
    Naccarelli GV, Fineberg NA, Zipes DP et al (1985) Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 6: 814PubMedCrossRefGoogle Scholar
  24. 24.
    Morady F, Scheinman MM, Hess DS (1983) Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. PACE 6: 609PubMedGoogle Scholar
  25. 25.
    Sokoloff NN, Spielman SR, Greenspan AM et al (1986) Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone. J Am Coll Cardiol 7: 938PubMedCrossRefGoogle Scholar
  26. 26.
    DiCarlo LA Jr, Morady F, Sauve MJ et al (1985) Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: Risk stratification based on clinical variables. Am J Cardiol 55: 372PubMedCrossRefGoogle Scholar
  27. 27.
    Borggrefe M, Breithardt G (1986) Predictive value of electrophysiologic testing in the treatment of drug- refractory ventricular arrhythmias with amiodarone. European Heart J 7: 735–742Google Scholar
  28. 28.
    Alboni P, Shantha N, Pirani R, Baggioni F, Scarfo’ S, Tomasi AM, Masoni A (1984) Effects of amiodarone on supraventricular tachycardia involving bypass tracts. Am J Cardiol 53: 93–98PubMedCrossRefGoogle Scholar
  29. 29.
    Feld GK, Nademanee K, Weiss J, Stevenson W, Singh BN (1984) Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol 3: 1298–1307PubMedCrossRefGoogle Scholar
  30. 30.
    Rowland E, Krikler D (1980) Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J 44: 82–90PubMedCrossRefGoogle Scholar
  31. 31.
    Wellens HJJ, Brugada P, Abdullah H (1983) Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrom. Am Heart J 106: 876–879PubMedCrossRefGoogle Scholar
  32. 32.
    Brugada P, Wellens HJJ (1985) Effects of oral amiodarone on rate-dependent changes in refractoriness in patients with Wolff-Parkinson-White syndrome. Am J Cardiol 56: 863–866PubMedCrossRefGoogle Scholar
  33. 33.
    Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM (1983) Side effects of long-term amiodarone therapy. Circulation 67: 45–51PubMedCrossRefGoogle Scholar
  34. 34.
    Raeder EA, Podrid PJ, Lown B (1985) Side effects and complications of amiodarone therapy. Am Heart J 109: 975PubMedCrossRefGoogle Scholar
  35. 35.
    Lavery D, Saksena S, Gordon S et al (1986) Long-term efficacy of amiodarone therapy in refractory sustained ventricular tachycardia: The role of electrophysiologic studies and ambulatory monitoring. J Am Coll Cardiol 7: 91A (Abstr)CrossRefGoogle Scholar
  36. 36.
    Kennedy EE, Batsford WP, Rosenfled LE et al (1984) Predicting therapeutic efficacy with amiodarone: a combined Holter/electrophysiologic approach. J Am Coll Cardiol 3: 605Google Scholar
  37. 37.
    Chua W, Roth H, Summers C et al (1983) Programmed stimulation versus ambulatory monitoring for therapy of malignant arrhythmias. Circulation 68: III–55Google Scholar
  38. 38.
    Kim SG, Felder SD, Figeura I et al (1986) Predictive accuracies of Holter monitoring and programmed stimulation in patients taking amiodarone. J Am Coll Cardiol 7: 143 A (Abstr)CrossRefGoogle Scholar
  39. 39.
    Stamato NJ, Marchlinski FE (1986) Role of Holter monitoring in the management of patients with ventricular tachycardia treated with amiodarone. Clin Prog Electrophysiol Pacing 4: 395–401Google Scholar
  40. 40.
    Denes P, Wu D, Dhingra RC, Amat-y-Leon F, Wyndham C, Mautrer RK, Rosen KM (1976) Electrophysiolical studies in patients with chronic recurrent ventricular tachycardia. Circulation 54: 229–236PubMedGoogle Scholar
  41. 41.
    Josephson ME, Horowitz LN, Farshidi A, Kastor JA (1978) Recurrent sustained ventricular tachycardia. 1. Mechanismus. Circulation 57: 431–440PubMedGoogle Scholar
  42. 42.
    Fisher JD, Cohen HL, Mehra R, Altschuler H, Eschwer DJW, Furman S (1977) Cardiac pacing and pacemakers. II. Serial electrophysiologic-pharmacologic testing for control of recurrent tachyarrhythmias. Am Heart J 93: 658–668PubMedCrossRefGoogle Scholar
  43. 43.
    Hartzler GO, Maloney JD (1977) Programmed ventricular stimulation in management of recurrent ventricular tachycardia. Mayo Clin Proc 52: 731–741PubMedGoogle Scholar
  44. 44.
    Wu D, Wyndham CR, Denes P, Amat-y-Leon F, Miller RH, Dhingra RC, Rosen KM (1977) Chronic electrophysiological study in patients with recurrent paroxysmal tachycardia: a new method for developing successful oral antiarrhythmic therapy. In: Kulbertus HE (Ed) (1977) Re-entrant arrhythmias. Mechanisms and treatment. MTP Lancaster, 294–311Google Scholar
  45. 45.
    Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AN (1978) Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 58: 986–997PubMedGoogle Scholar
  46. 46.
    Mason JW, Winkle RA (1978) Electrode catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 58: 971–985PubMedGoogle Scholar
  47. 47.
    Breithardt G, Seipel L, Abendroth R-R, Loogen F (1980) Serial electrophysiological testing of antiarrhythmic drug efficacy in patients with recurrent ventricular tachycardia. Europ Heart J 1: 11–24Google Scholar
  48. 48.
    Denes P, Wu D, Wyndham C, Dhingra R, Bauernfeind RA, Swiryn S, Rosen KM (1980) Chronic long-term electrophysiologic study of paroxysmal ventricular tachycardia. Chest 77: 478–487PubMedCrossRefGoogle Scholar
  49. 49.
    Horowitz LN, Josephson ME, Kastor J A (1980) Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmia. Prog Cardiovasc Dis 23: 81–98PubMedCrossRefGoogle Scholar
  50. 50.
    Mason J, Winkle RA (1980) Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy of antiarrhythmic drugs. N Engl J Med 303: 1073–1077PubMedCrossRefGoogle Scholar
  51. 51.
    Swerdlow CH, Winkle RA, Mason JA (1983) Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 308: 1436–1442PubMedCrossRefGoogle Scholar
  52. 52.
    Borggrefe M, Breithardt G (1986) Abgestufte Kriterien zur Beurteilung der Effektivität einer antiarrhythmi- schen Therapie bei Patienten mit ventrikulären Tachyarrhythmien mittels serieller elektrophysiologischer Testung. Z Kardiol 75: 70–79PubMedGoogle Scholar
  53. 53.
    Wyndham CR, Krafchek J, Nielsen A, Hargis J, Velasco CE, Magro S (1985) Improved prediction of outcome by serial electrophysiologic tests on amiodarone. Circulation 72 suppl-III: 273 (Abstract)Google Scholar
  54. 54.
    Borggrefe M, Podczeck A, Breithardt G (1986) Usefulness of early versus late electrophysiologic testing in patients with ventricular tachyarrhythmias treated with amiodarone. Circulation 74 suppl-II: 223 (Abstract)Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1987

Authors and Affiliations

  • M. Borggrefe
    • 2
  • A. Podczeck
    • 1
  • G. Breithardt
    • 1
  1. 1.Medizinische Klinik und Poliklinik, Abteilung für Kardiologie, Pneumologie und Angiologie der Universität DüsseldorfGermany
  2. 2.Medizinische Klinik und Poliklinik Abteilung für Kardiologie, Pneumologie und AngiologieUniversität DüsseldorfDüsseldorf 1Germany

Personalised recommendations